Get the Stockscreener App
10.13
7.18%
-0.81
Trevi Therapeutics Inc stock is traded at $10.13, with a volume of 297.61K.
It is down -7.18% in the last 24 hours and down -20.79% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$10.94
Open:
$10.89
24h Volume:
297.61K
Relative Volume:
0.17
Market Cap:
$1.30B
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-34.93
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
-3.10%
1M Performance:
-20.79%
6M Performance:
+28.71%
1Y Performance:
+154.51%
1-Day Range:
$10.12
$11.09
1-Week Range:
$10.15
$11.15
52-Week Range:
$3.771
$14.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
10.13 | 1.40B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Initiated | Morgan Stanley | Overweight |
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics (TRVI) Publishes Positive Phase 2b Trial Resu - GuruFocus
Experimental cough pill lets most IPF patients cut daily coughing in half - Stock Titan
Aug Action: Is Trevi Therapeutics Inc a top pick in the sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Is Trevi Therapeutics Inc. stock technically oversoldBear Alert & Accurate Buy Signal Alerts - bollywoodhelpline.com
New trial links cough counts to how IPF patients feel on oral treatment - Stock Titan
Will Trevi Therapeutics Inc outperform tech stocksPortfolio Gains Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN
Coulter Partners successfully led a search assignment for Trevi Therapeutics, Inc. (Nasdaq: TRVI) and is pleased to announce the placement of David Hastings as Chief Financial Officer (CFO) - Hunt Scanlon Media
Trevi Therapeutics (TRVI) targets next phase of growth with leadership change - MSN
Aug Technicals: Can Trevi Therapeutics Inc continue delivering strong returns - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of “Buy” by Brokerages - Defense World
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism - Yahoo Finance
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? - Yahoo Finance
Peregrine Capital Management LLC Invests $5.68 Million in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at HC Wainwright - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from HC Wainwright - MarketBeat
Trevi Therapeutics (TRVI) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | TRVI Stock News - GuruFocus
Trevi Therapeutics’ (TRVI) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - Sahm
Published on: 2026-01-09 09:26:05 - Улправда
Will Trevi Therapeutics Inc. stock maintain momentum in 2025Quarterly Growth Report & Long Hold Capital Preservation Plans - Улправда
Will Trevi Therapeutics Inc. stock split again soonJuly 2025 Macro Moves & Community Consensus Trade Alerts - Улправда
Growth Value: Can Trevi Therapeutics Inc. stock maintain growth trajectoryProfit Target & Verified Entry Point Signals - ulpravda.ru
Can Trevi Therapeutics Inc. stock maintain growth trajectoryJuly 2025 Intraday Action & Reliable Breakout Stock Forecasts - Улправда
Sentiment Recap: Can TPIC stock surprise with earnings upsideJuly 2025 Earnings & Comprehensive Market Scan Insights - moha.gov.vn
Aug Shorts: Can Trevi Therapeutics Inc stock maintain growth trajectory2025 Winners & Losers & Reliable Momentum Entry Alerts - Bộ Nội Vụ
What dividend safety score for Trevi Therapeutics Inc. stockPortfolio Profit Report & Weekly High Potential Alerts - Улправда
Trevi Therapeutics Outlines Key Development Milestones for Lead Drug Candidate - AD HOC NEWS
Is Trevi Therapeutics Inc. stock trading at a premium valuation2025 Sector Review & Capital Efficiency Focused Strategies - Улправда
Trevi Therapeutics schedules FDA meeting for chronic cough program By Investing.com - Investing.com India
Will Trevi Therapeutics Inc. stock gain from strong economy2025 Institutional Moves & Technical Buy Zone Confirmation - Улправда
Will Trevi Therapeutics Inc. stock rally after Fed decisionsJuly 2025 Opening Moves & Stock Portfolio Risk Management - Улправда
Why Trevi Therapeutics Inc. stock remains on buy listsJuly 2025 EndofMonth & Weekly Watchlist for Consistent Profits - Улправда
Published on: 2026-01-08 19:22:53 - ulpravda.ru
Why Trevi Therapeutics Inc. stock could outperform in 2025Quarterly Profit Review & AI Powered Buy/Sell Recommendations - Улправда
Trevi Therapeutics (TRVI) Analyst Rating Update: Buy Rating Main - GuruFocus
Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Trevi Therapeutics schedules FDA meeting for chronic cough program - Investing.com
TRVI Stock Falls -15% With A 7-day Losing Spree On Technical Breakdown - Trefis
Published on: 2026-01-03 15:10:39 - moha.gov.vn
Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 6.3%Here's Why - MarketBeat
Quarterly Recap: What dividend safety score for Trevi Therapeutics Inc stockStock Surge & AI Optimized Trading Strategy Guides - moha.gov.vn
Published on: 2025-12-31 06:38:59 - moha.gov.vn
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - MSN
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change - Finviz
Flputnam Investment Management Co. Raises Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Is Trevi Therapeutics Inc. stock cheap at current valuationJuly 2025 PreEarnings & High Yield Equity Trading Tips - Улправда
Stifel Maintains Trevi Therapeutics (TRVI) Buy Recommendation - Nasdaq
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - MSN
Trevi Therapeutics stock price target raised to $18 by Stifel on cough drug potential - Investing.com Canada
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):